# CASSIOPEIA (NCT03876769)

> Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03876769
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: B-Cell Acute Lymphoblastic Leukemia
- Interventions: CTL019
- Enrollment: 121
- Primary outcome: Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission
- Primary outcome: Overall Survival (OS) rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 136
- YouTube: 86
- Podcasts: 52

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cassiopeia-nct03876769

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03876769", "email": "<work email>"}; the inbox owner confirms by the emailed link.